| |
 |
Case Studies
|
|
|
| Product Launch Sequence |
Objectives
To recommend the ideal launch sequence (to optimise commercial opportunity and maintain achievable price levels) for 3 separate products
Therapy Area
Renal
Client
German pharmaceutical company
Product/Technology
Drugs
Scope
36 countries across Western and Eastern Europe, Middle East and Northern and South Africa
ABPPC Workplan
Modelled optimal launce sequences using ABPPC External Reference Price (ERP) Database and price and forecast data from client
Project Duration
8 days
Outcome
Ideal launch sequence and rationale provided for each of the 3 products, including details of how ERP affects each country.
|
|
|
Back to top
|
|
| Due Diligence Assessment for 2 agents |
Objectives
To assess the prospective pricing and reimbursement (P&R) environment for 2 novel formulation drugs to support client’s decision whether to in-licence the products.
Therapy Area
GI
Client
UK pharmaceutical company
Product/Technology
Drugs
Scope
UK, Germany, France, Spain, Italy and Netherlands
ABPPC Workplan
Compared agents with appropriate comparator agents and P&R proxies for novel formulation drugs and considered relevant state P&R regulations
Project Duration
13 days
Outcome
Analysis recommended favourable P&R environment for both agents and advocated proceeding with in-licence. Also guidance provided for necessary clinical programmes and data needs to achieve optimal P&R.
|
|
|
Back to top
|
|
| European Pricing and Reimbursement (P&R) Planning |
Objectives
To advise on such as clinical programme, reimbursement needs, market access, representational and distribution issues for new technology
Therapy Area
Oncology
Client
USA device company
Product/Technology
Device incorporating stem cell technology
Scope
UK, Germany, France, Italy, Spain, Netherlands
ABPPC Workplan
Consulted with appropriate in-market stakeholders (clinicians, regulators, payers, pharmacists, logistics) to assess respective issues and provide recommendations
Project Duration
12 weeks
Outcome
Guidance provided on all pertinent issues including on clinical programme design and appropriate QoL instrument for clinical study, DRG (diagnosis related groups) issues and actions, price guidance, specific reimbursement processes and activities and suggested in-market prelaunch activities.
|
|
|
Back to top
|
|
| European Patent Expiry Planning |
Objectives
To assess European sales impact of lowering price of brand in selective countries where patent soon expiring
Therapy Area
Arthritis
Client
Spanish pharmaceutical company
Product/Technology
Drug
Scope
UK, Germany, France, Italy, Spain, Netherlands, Belgium, Portugal, Greece
ABPPC Workplan
Modelled likely impacts of price reductions using ABPPC External Reference Price (ERP) Database and ABPPC Parallel Trade Model, in various scenarios based on client forecast data
Project Duration
15 days
Outcome
Modelled 4 different scenarios and presented summarised overall findings including revenue impact of adopting different pricing scenarios and ABPPC’s recommended approach.
|
|
|
Back to top
|
|
| Product Pricing and Reimbursement Strategy & Assessment of Client Structure and Processes |
Objectives
Developing the P&R strategy for 2 products as case studies to help review current P&R practice and processes within the client with a view to establishing improved and earlier decision-making
Therapy Area
Neurology & Haematology
Client
UK diagnostics company
Product/Technology
Diagnostics
Scope
USA, UK, Germany, France, Italy, Spain
ABPPC Workplan
Discussions with internal staff in marketing and other functions supplemented by in-market discussions with payers and hospital staff with analysis drawn from both aspects
Project Duration
5 months
Outcome
Recommendations provided on P&R strategy and necessary market access activities for each product as well as on an improved, integrated structure and decision process for development products
|
|
|
Back to top
|
|
| International Reimbursement Planning |
Objectives
To establish data needs and activities required to achieve reimbursement and market access
Therapy Area
Allergy
Client
Danish pharmaceutical company
Product/Technology
Vaccine
Scope
11 European countries
ABPPC Workplan
Development of product profile and discussion template followed by fieldwork discussions in each market and analysis of issues
Project Duration
16 weeks
Outcome
119 page report and summary presentation provided of ABPPC’s findings and recommendations including health economic requirements, reimbursement issues, necessary clinical data and in-market pre-launch activity plan.
|
|
|
Back to top
|
|
| Pricing and Reimbursement Implementation |
Objectives
To secure P&R in selective territories where the client had no affiliate/entity
Therapy Area
Epilepsy
Product/Technology
Drug
Scope
Benelux, Greece, Portugal, Hungary, Czech Republic and Poland
ABPPC Workplan
ABPPC developed submission and appropriate supportive materials and then liaised with appropriate State Authority to submit and secure P&R
Project Duration
6 months+
Outcome
P&R achieved in the designated territories with market access strategies developed for those countries where the desired P&R were difficult to achieve.
|
|
|
Back to top
|
|
| Pricing and Reimbursement Strategy and Launch Planning |
Objectives
To develop P&R strategy, assess pre-approval use possibilities and identify any specific local issues
Therapy Area
Orphan inherited disease
Client
USA Biopharmaceutical company
Product/Technology
Drug
Scope
15 European countries
ABPPC Workplan
ABPPC developed product profile and discussion guide followed by Key Opinion Leader (KOL) and payer discussions in each territory
Project Duration
12 weeks
Outcome
Provided 118 page report and a summary presentation of findings and recommendations including in-market and international pricing strategy, optimal launch sequence, reimbursement data needs, identifying main likely treatment centres and markets where a pre-approval use availability was advocated. |
|
|
|
|
| |
|
|
